Beichert Lukas, Ilg Winfried, Kessler Christoph, Traschütz Andreas, Reich Selina, Santorelli Filippo M, Başak Ayşe Nazli, Gagnon Cynthia, Schüle Rebecca, Synofzik Matthis
Division Translational Genomics of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center for Neurology, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany.
Mov Disord. 2024 Sep;39(9):1544-1555. doi: 10.1002/mds.29876. Epub 2024 Jun 7.
With treatment trials on the horizon, this study aimed to identify candidate digital-motor gait outcomes for autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), capturable by wearable sensors with multicenter validity, and ideally also ecological validity during free walking outside laboratory settings.
Cross-sectional multicenter study (four centers), with gait assessments in 36 subjects (18 ARSACS patients; 18 controls) using three body-worn sensors (Opal, APDM) in laboratory settings and free walking in public spaces. Sensor gait measures were analyzed for discriminative validity from controls, and for convergent (ie, clinical and patient relevance) validity by correlations with SPRS (primary outcome) and Scale for the Assessment and Rating of Ataxia (SARA), Spastic Paraplegia Rating Scale (SPRS), and activities of daily living subscore of the Friedreich Ataxia Rating Scale (FARS-ADL) (exploratory outcomes).
Of 30 hypothesis-based digital gait measures, 14 measures discriminated ARSACS patients from controls with large effect sizes (|Cliff's δ| > 0.8) in laboratory settings, with strongest discrimination by measures of spatiotemporal variability Lateral Step Deviation (δ = 0.98), SPcmp (δ = 0.94), and Swing CV (δ = 0.93). Large correlations with the SPRS were observed for Swing CV (Spearman's ρ = 0.84), Speed (ρ = -0.63), and Harmonic Ratio V (ρ = -0.62). During supervised free walking in a public space, 11/30 gait measures discriminated ARSACS from controls with large effect sizes. Large correlations with SPRS were here observed for Swing CV (ρ = 0.78) and Speed (ρ = -0.69), without reductions in effect sizes compared with laboratory settings.
We identified a promising set of digital-motor candidate gait outcomes for ARSACS, applicable in multicenter settings, correlating with patient-relevant health aspects, and with high validity also outside laboratory settings, thus simulating real-life walking with higher ecological validity. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
鉴于即将开展治疗试验,本研究旨在确定可穿戴传感器能够捕捉的、具有多中心效度且理想情况下在实验室外自由行走时具有生态效度的常染色体隐性遗传性夏勒沃-萨格奈痉挛性共济失调(ARSACS)的数字运动步态候选指标。
开展横断面多中心研究(四个中心),在实验室环境中对36名受试者(18名ARSACS患者;18名对照)进行步态评估,使用三种可穿戴在身体上的传感器(Opal、APDM),并在公共场所进行自由行走。分析传感器步态测量指标与对照组相比的判别效度,以及通过与痉挛性截瘫评定量表(SPRS,主要结局指标)、共济失调评估与分级量表(SARA)、痉挛性截瘫评定量表(SPRS)以及弗里德赖希共济失调评定量表日常生活活动子量表(FARS-ADL)(探索性结局指标)的相关性来分析其收敛效度(即临床和患者相关性)。
在30项基于假设的数字步态测量指标中,有14项指标在实验室环境中能够有效区分ARSACS患者与对照组,效应量较大(|Cliff's δ|>0.8),其中时空变异性指标横向步幅偏差(δ = 0.98)、SPcmp(δ = 0.94)和摆动期变异系数(δ = 0.93)的区分能力最强。摆动期变异系数(Spearman相关系数ρ = 0.84)、速度(ρ = -0.63)和谐波比V(ρ = -0.62)与SPRS的相关性较高。在公共场所进行监督下的自由行走时,30项步态测量指标中有11项能够有效区分ARSACS患者与对照组,效应量较大。在此观察到摆动期变异系数(ρ = 0.78)和速度(ρ = -0.69)与SPRS的相关性较高,与实验室环境相比效应量没有降低。
我们为ARSACS确定了一组有前景的数字运动步态候选指标,适用于多中心研究,与患者相关的健康方面相关,并且在实验室外也具有高效度,从而以更高的生态效度模拟现实生活中的行走。© 2024作者。《运动障碍》由Wiley Periodicals LLC代表国际帕金森和运动障碍协会出版。